Curaleaf Holdings Inc (CURA.TO) Buy, Sell or…

Home

Daily Stock Opinions and Ratings

Curaleaf Holdings Inc (CURA.TO)

13.14

+0.02 (0.15%)

as of Jul 17, 2026, 8:00:00 pm Market Open.

119 watching

Investor Insights

Jul 19, 2026, 12:00 am

This summary was created by AI, based on 5 opinions in the last 12 months.

Curaleaf Holdings Inc. (CURA-T) has garnered mixed reviews from experts highlighting the volatility and uncertainty surrounding the cannabis sector, particularly due to potential changes in regulatory frameworks. A significant factor in the company's outlook is the anticipation of cannabis being rescheduled, which could lead to improved taxation conditions and enhanced cash flow for the industry. Nevertheless, the timeline for such changes remains unpredictable, making it essential for investors to approach with caution and consider only a small investment until cash flow stabilizes. Furthermore, while there is optimism about the sector's growth, driven by state-level legalization and the cleaned-up financials of companies, experts warn that a return to previous lows is also possible. Ultimately, the cannabis market remains a commoditized and speculative space, requiring careful navigation by potential investors.

Consensus

Cautious

Valuation

Undervalued

Similar

Trulieve,TCNNF

TOP PICK

Operates entirely in the US. Largest marijuana producer in the world by sales. Vertically integrated. Growing quickly organically and by acquisition. Regulatory tailwind. Democrats taking Senate increase likelihood of legislative reform. Great company, lots of growth runway. No dividend. (Analysts’ price target is $19.98)

BUY

It's the largest US MSO (multi-state operator) in several U.S. states. They've built up a small private company over two years, then went public. MSOs are capturing more attention and capital flows.

TOP PICK

Operates entirely in US, with 10x the market. Canadian red tape has made it difficult for regulated companies to take market share from black market. Whereas US market is undersupplied. Vertical integration and geographic diversity are part of its strategy. Good management. No dividend. (Analysts’ price target is $17.47)

HOLD

He finds it fascinating that cannabis is still illegal in the US, but is deemed essential during the pandemic. He thinks this will lead to relaxed regulations in the future. The company generates increasing revenue and positive cash flow -- only a handful of US cannabis companies do. He thinks it will be a dominant player in years to come in the space.

BUY

CURELF-N vs. CL-X. He really made a focus on the US for cannabis. He thinks the US MSOs have a tremendous amount of room to go. CURELF-N is one of the leaders. CL-X just did a deal in California, which is one of the biggest markets out there. He likes both of them. They are both leaders.

Showing 31 to 35 of 35 entries

Most Recent Experts

Malcolm Ethridge, Mgn. partner, Capital Area Planning Group

Capital Area Planning Group

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Kevin Simpson

Capital Wealth Planning

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Bruce Campbell (2)

Stone Castle Investment Management Inc.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Curaleaf Holdings Inc (CURA.TO)